MétaCan
Menu
Back to cohort
Record W2170104292 · doi:10.1177/135965350400900512

Quality of Life in Patients Treated with First-Line Antiretroviral Therapy Containing Nevirapine And/Or Efavirenz

2004· article· en· W2170104292 on OpenAlexaff
Frank van Leth, Brian Conway, H. Laplume, Des Martin, Martin Fisher, Ante Jelaska, Ferdinand W.N.M. Wit, Joep MA Lange, MB Lasala, MH Losso, E Bogdanowicz, R. Lattes, Alejandro Krolewiecki, Carlos Zala, Carloandrea Orcese, Samira Terlizzi, Adriana Durán, J Ebensrteijn, Mark Bloch, O Russell, DB Russell, NR Roth, Beng Eu, David Austin, Andrew Gowers, Dick Quan, J Demonty, Renaat Peleman, Bernard Vandercam, Dirk Vogelaers, B van der Gucht, Filip Van Wanzeele, MM Moutschen, Roberto Badaró, Beatriz Grinsztejn, Martin T. Schechter, David Éverson Uip, EN Netto, SS Coelho, F. Badaró, JH Pilotto, A Schubach, ML Barros, O. H. M. Leite, CRV Kiffer, CT Wunsch, Daniela Nunes, A. Catalani, Lira R de Cassia Alves, TJ Dossin, MT D'Alló de Oliveira, Salvatore Martini, JJ de Wet, JSG Montaner, Cynthia Murphy, Brian Woodfall, P Sestak, Peter Phillips, Valentina Montessori, Marianne Harris, Alicja M. Tesiorowski, Brian J. Willoughby, Robin M. Voigt, John Farley, Richard Reynolds, Stanley DeVlaming, JM Livrozet, Willy Rozenbaum, D. Séréni, M.A. Valantin, C. Lascoux, B. Milpied, C. Brunet, Éric Billaud, A. Huart, Véronique Reliquet, MF Charonnat, Marion Sicot, JL Esnault, Laurence Slama, S Staszewski, M. Bickel, MK Lazanas, N.G. Stavrianeas, Nikos Mangafas, Ioannis Zagoreos, Sofia Kourkounti, Vassilios Paparizos, Ch Botsi, Eimear Brannigan, N Boyle, A Chiriani, F Leoncini, Francesco Montella, Silvia Ambu, Alberto Farese, Miriam Gargiulo, Fiorella Di Sora, F Lavria, F. Folgori, Marek Beniowski, A Boron Kaczmarska, Waldemar Halota, D Prokopowicz, DB Bander, MLP Leszuzyszyn-Pynka, AW Wnuk, Elżbieta Bąkowska, Piotr Pulik, Robert Flisiak, E. Mularska, Adam Witor, Francisco Antunes, RSE Sarmento, Manuela Doroana, A. Mota Horta, O Vasconcelos, SM Andrews, CB Huisamen, David W. Johnson, Oriol Martín‐Solé, Gary Maartens, Darren Wilson, CJ Visagie, NJ David, M. Rattley, Edna Nettleship, Martin Dj, Valerie Keyser, TM Moraites, MA Moorhouse, JA Pitt, CJ Orrell, C.J. Bester, Raveen Parboosing, Pravi Moodley, V Gathiram, David Woolf, Enos Bernasconi, Lorenzo Magenta, Peter Cardiello, Eugène Kroon, Chaiwat Ungsedhapand, EGL Wilkins, E. Stockwell, Jeremy Day, RS Daintith, Nicky Perry, C Timaeus, J Mc Intosh-Roffet, Anna Powell, M Youle, Mervyn Tyrer, Sara Madge, Anthony Drinkwater, Zoe Cuthbertson, Annemaree Carroll, Simone Becker, Harold Katner, David Rimland, Saag Ms, Melanie Thompson, Mallory D. Witt, MM Aguilar, Alora LaVoy, Mark L Illeman, Manuel Fernández Guerrero, JM Gatell, E M Belsey, Bernard Hirschel, Antonia Potarca, M Cronenberg, L Kreekel, Reinier G.S. Meester, J Khodabaks, H.J Botma, N Esrhir, Ida Farida, Minke L. Feenstra, Klaus Jansen, Adam Klotz, Maximilian Mulder, Gerrina Ruiter, CB Bass, E Pluymers, E de Vlegelaer, R Leeneman, Hilde Carlier, E. Van Steenberge, D. B. Hall

Bibliographic record

VenueAntiviral Therapy · 2004
Typearticle
Languageen
FieldMedicine
TopicHIV/AIDS drug development and treatment
Canadian institutionsUniversity of British Columbia
Fundersnot available
KeywordsNevirapineEfavirenzMedicineInternal medicineStavudineAdverse effectLamivudineQuality of life (healthcare)Health related quality of lifeViral loadAntiretroviral therapyHuman immunodeficiency virus (HIV)VirologyDisease

Abstract

fetched live from OpenAlex

OBJECTIVE: To assess whether differences in safety profiles between nevirapine (NVP) and efavirenz (EFV), as observed in the 2NN study, translated into differences in 'health related quality of life' (HRQoL). DESIGN: A sub-study of the 2NN study, with antiretroviral-naive patients randomly allocated to NVP (once or twice daily), EFV or NVP+EFV, in addition to stavudine and lamivudine. METHODS: Comparing differences in changes of HRQoL over 48 weeks as measured with the Medical Outcomes Study HIV Health Survey (MOS-HIV) questionnaire, using analysis of variance. RESULTS: The 2NN study enrolled 1216 patients. No validated questionnaires were available for 244 patients, and 55 patients had no HRQoL data at all, leaving 917 patients eligible for this sub-study. A total of 471 (51%) had HRQoL measurements both at baseline and week 48. The majority (69%) of patients without HRQoL measurements did, however, complete the study. The change in the physical health score (PHS) was 3.9 for NVP, 3.4 for EFV and 2.4 for NVP+EFV (P=0.712). For the mental health score (MHS) these values were 6.1, 7.0 and 3.9, respectively (P=0.098). A baseline plasma HIV-1 RNA concentration (pVL) > or = 100,000 copies/ml and a decline in pVL (per log10) were independently associated with an increase of PHS. An increase of MHS was only associated with pVL decline. Patients experiencing an adverse event during follow-up had a comparable change in PHS but a significantly smaller change in MHS, compared with those without an adverse event. CONCLUSIONS: First-line ART containing NVP and/or EFV leads to an improvement in HRQoL. The gain in HRQoL was similar for NVP and EFV, but slightly lower for the combination of these drugs.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.033
Threshold uncertainty score0.770

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.039
GPT teacher head0.299
Teacher spread0.260 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations28
Published2004
Admission routes1
Has abstractyes

Explore more

Same venueAntiviral TherapySame topicHIV/AIDS drug development and treatmentFrench-language works237,207